4-(3,4-dichloro-phenyl)-4-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-pyrrolidine | 155308-39-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 4-(3,4-dichloro-phenyl)-4-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-pyrrolidine
• 英文别名: 3-(3,4-Dichlorophenyl)-3-(2-[tetrahydropyran-2-yloxy]ethyl)pyrrolidine；3-(2-Tetrahydropyranyloxyethyl)-3-(3,4-dichlorophenyl)pyrrolidine；3-Tetrahydropyranyloxyethyl-3-(3,4-dichlorophenyl)pyrrolidine；3-(3,4-dichlorophenyl)-3-[2-(oxan-2-yloxy)ethyl]pyrrolidine
• CAS: 155308-39-7
• 化学式: C₁₇H₂₃Cl₂NO₂
• 分子量: 344.281
• InChiKey: PFFOGNPFQBFEGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3,4-dichloro-phenyl)-4-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-pyrrolidine 在 盐酸 、 sodium hydroxide 、 sodium chloride 作用下， 以 甲醇 、 异丙醚 、 水 为溶剂， 生成 2-(3-(3,4-二氯苯基)吡咯烷-3-基)乙醇
  参考文献：
  名称：

  1-azoniabicyclo\x9b2.2.1!heptanes, method of preparing them and

  摘要：

  该发明涉及公式为##STR1##的四元碱性酰胺，其中Ar是一个可选择取代的单环、双环或三环芳香或杂芳基团；T是直链键，羟甲亚基，烷氧甲亚基，其中烷氧基是C.sub.1 -C.sub.4，或C.sub.1 -C.sub.5-烷基亚基；Ar'是未取代或单取代或多取代的苯基，噻吩基，苯噻吩基，萘基或吲哚基；R是氢或C.sub.1 -C.sub.4-烷基，或C.sub.1 -C.sub.4-ω-烷氧基(C.sub.2 -C.sub.4)烷基，或C.sub.2 -C.sub.4-ω-烷酰氧基(C.sub.1 -C.sub.4)烷基；Q是氢；或者Q和R一起形成1,2-乙烯，1,3-丙烯或1,4-丁烯基团；Am.sup..sym.是基团##STR2##其中X.sub.1、X.sub.2和X.sub.3与它们连接的氮原子一起形成一个1-AZONIABICYCLO\x9b2.2.1!HEPTANE，该环可选择由苯基或苄基取代；A.sup..crclbar.是一种药用可接受的阴离子。这些化合物可用于制备用于治疗涉及Tachykinin系统的病理条件的药物。

  公开号：

  US05679693A1
• 作为产物：
  描述：

  4-(3,4-dichloro-phenyl)-4-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-pyrrolidin-2-one 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 4-(3,4-dichloro-phenyl)-4-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-pyrrolidine
  参考文献：
  名称：

  4-Amino-2-(aryl)-butylbenzamides and Their conformationally constrained analogues. Potent antagonists of the human neurokinin-2 (NK2) receptor

  摘要：

  A library, evaluating a range of piperazines, piperidines and acyclic amines, as replacements for the 4-hydroxy-4-phenylpiperidine moiety in lead (1b) was prepared. These efforts identified the 4-((N)-benzimidazolone)piperidine analogue (2a) which was further optimised using classical single-compound synthesis to yield the 3-((N)-morpholino)azetidine (2j). Conformationally constrained analogues of (2j), generally offered no potency advantage in this particular series. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00343-3

文献信息

• Substituted pyrrolidin-3-yl-alkyl-piperidines
  申请人：Merrell Pharmaceuticals Inc.

  公开号：US05635510A1

  公开（公告）日：1997-06-03

  The present invention relates to substituted pyrrolidinyl-3-yl-alkyl-piperidines, their stereoisomers, and pharmaceutically acceptable salts thereof and processes for preparation of the same. The compounds of the present invention are useful in their pharmacological activities such as tachykinin antagonism, especially substance P and neurokinin A antagonism, and the like. Compounds having the property of tachykinin antagonism are indicated for conditions associated with neurogenic inflammation and other diseases described herein.

  本发明涉及取代吡咯啉基-3-基-烷基-哌啶、其立体异构体和药学上可接受的盐以及其制备方法。本发明的化合物在药理活性方面具有用途，如快速激肽拮抗作用，特别是物质P和神经激肽A的拮抗作用等。具有快速激肽拮抗性质的化合物适用于与神经源性炎症和本文所述的其他疾病相关的情况。
• 1-azoniabicyclo[2.2.1] heptanes and pharmaceutical compositions in which
  申请人：Sanofi

  公开号：US05554763A1

  公开（公告）日：1996-09-10

  The invention relates to quaternary basic amides of the formula ##STR1## in which Ar is an optionally substituted mono-, di- or tri-cyclic aromatic or heteroaromatic group; T is a direct bond, a hydroxymethylene group, an alkoxymethylene group in which the alkoxy group is C.sub.1 -C.sub.4, or a C.sub.1 -C.sub.5 -alkylene group; Ar' is an unsubstituted or mono- or poly-substituted phenyl, a thienyl, a benzothienyl, a naphthyl or an indolyl; R is hydrogen or a C.sub.1 -C.sub.4 -alkyl, or a .omega.-C.sub.1 -C.sub.4 -alkoxy(C.sub.2 -C.sub.4)alkyl, or a .omega.-C.sub.2 -C.sub.4 -alkanoyloxy (C.sub.1 -C.sub.4)alkyl;. Q is hydrogen; or else Q and R together form a 1,2-ethylene, 1,3-propylene or 1,4-butylene group; Am.sup..sym. is the radical ##STR2## in which X.sub.1, X.sub.2 and X.sub.3, together with the nitrogen atom to which they are bonded, form an azabicyclic or azatricyclic system optionally substituted by a phenyl or benzyl group; and A.sup..crclbar. is a pharmaceutically acceptable anion. These compounds are useful for the preparation of drugs intended for the treatment of pathological conditions involving the tachykinin system.

  该发明涉及以下结构的四元碱性酰胺：其中Ar是可选择取代的单、双或三环芳香族或杂芳族基团；T是直接键、羟甲亚基、烷氧基甲亚基（其中烷氧基是C.sub.1 -C.sub.4）、或C.sub.1 -C.sub.5 烷基亚基；Ar'是未取代或单或多取代的苯基、噻吩基、苯并噻吩基、萘基或吲哚基；R是氢或C.sub.1 -C.sub.4 烷基，或.ω.-C.sub.1 -C.sub.4 烷氧基(C.sub.2 -C.sub.4)烷基，或.ω.-C.sub.2 -C.sub.4 烷酰氧基(C.sub.1 -C.sub.4)烷基；Q是氢；或者Q和R一起形成1,2-乙烯基、1,3-丙烷基或1,4-丁烷基；Am.sup..sym.是基团：其中X.sub.1、X.sub.2和X.sub.3与它们连接的氮原子一起形成一个可能被苯基或苄基取代的氮杂双环或氮杂三环系统；A.sup..crclbar.是一种药用可接受的阴离子。这些化合物可用于制备用于治疗涉及缓激肽系统的病理状况的药物。
• Pyrrolidinyl tachykinin receptor antagonists
  申请人：Eli Lilly and Company

  公开号：US05607947A1

  公开（公告）日：1997-03-04

  This invention provides a novel series of substituted pyrrolidines which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.

  这项发明提供了一系列新型的取代吡咯烷衍生物，可用于治疗或预防与过量的快速肽相关的生理障碍。该发明还提供了用于治疗这种生理障碍的方法，以及采用这些新型化合物的制药配方。
• Quaternary basic amides, method of preparing them and pharmaceutical
  申请人：Sanofi

  公开号：US05712288A1

  公开（公告）日：1998-01-27

  The invention relates to quaternary basic amides of the formula ##STR1## in which Ar is an optionally substituted mono-, di- or tri-cyclic aromatic or heteroaromatic group; T is a direct bond, a hydroxymethylene group, an alkoxymethylene group in which the alkoxy group is C.sub.1 -C.sub.4, or a C.sub.1 -C.sub.5 -alkylene group; Ar' is an unsubstituted or mono- or poly-substituted phenyl, a thienyl, a benzothienyl, a naphthyl or an indolyl; R is hydrogen or a C.sub.1 -C.sub.4 -alkyl, or a C.sub.1 -C.sub.4 -.omega.-alkoxy(C.sub.2 -C.sub.4)alkyl, or a C.sub.2 -C.sub.4 -.omega.-alkanoyloxy (C.sub.1 -C.sub.4)alkyl; Q is hydrogen; or else Q and R together form a 1,2-ethylene, 1,3-propylene or 1,4-butylene group; Am.sup..sym. is the radical ##STR2## in which X.sub.1, X.sub.2 and X.sub.3, together with the nitrogen atom to which they are bonded, form a 1-azoniabicyclo\x9b2.2.2!octane optionally substituted by a phenyl or benzyl group; and A.sup..crclbar. is a pharmaceutically acceptable anion. These compounds are useful for the preparation of drugs intended for the treatment of pathological conditions involving the tachykinin system.

  本发明涉及公式##STR1##中的季铵基酰胺，其中Ar是一个可选的取代的单环、双环或三环芳香或杂芳基团；T是直接键，羟甲基烷基，其中烷氧基是C.sub.1-C.sub.4，或C.sub.1-C.sub.5-烷基烷基；Ar'是未取代或单取代或多取代的苯基、噻吩基、苯并噻吩基、萘基或吲哚基；R是氢或C.sub.1-C.sub.4-烷基，或C.sub.1-C.sub.4-ω-烷氧基(C.sub.2-C.sub.4)烷基，或C.sub.2-C.sub.4-ω-酰氧基(C.sub.1-C.sub.4)烷基；Q是氢；或者Q和R一起形成1,2-乙烯基、1,3-丙烯基或1,4-丁烷基；Am.sup..sym.是基团##STR2##其中X.sub.1、X.sub.2和X.sub.3与它们连接的氮原子一起形成一个可选取代的苯基或苄基的1-氮杂双环[2.2.2]辛烷；A.sup..crclbar.是一种药学上可接受的阴离子。这些化合物可用于制备用于治疗涉及Tachykinin系统的病理状况的药物。
• 1-azoniabicyclo[2.2.2] octanes and pharmaceutical compositions in which
  申请人：Sanofi

  公开号：US05583134A1

  公开（公告）日：1996-12-10

  The present invention relates to quaternary basic amides of the formula: ##STR1## These compounds are useful for the preparation of drugs intended for the treatment of pathological conditions involving the tachkinin system.

  本发明涉及公式为：##STR1## 的季铵基酰胺。这些化合物可用于制备用于治疗涉及缩氨酸系统的病理状况的药物。